Elicio Therapeutics, Inc. Restructuring Charges
Elicio Therapeutics, Inc. (ELTX) reported Restructuring Charges of $9.20 million for the 12-month period ending 2022-12-31, per its 10-Q filed 2023-05-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2023-05-10
- Elicio Therapeutics, Inc. restructuring charges for the quarter ending 2022-12-31 was $3.16M.
- Elicio Therapeutics, Inc. restructuring charges for the quarter ending 2022-09-30 was $2.80M.
- Elicio Therapeutics, Inc. restructuring charges for the quarter ending 2021-09-30 was $0.00.
| Period end | Restructuring Charges | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|---|
| 2022-12-31 | $3.16M derived: 10-Q 12 month − 10-Q 9 month · filed 2023-05-10 | $5.96M derived: sum of 2 quarters · filed 2023-05-10 | $9.20M 10-Q · filed 2023-05-10 | ||
| 2022-09-30 | $2.80M 10-Q · filed 2022-11-14 | $6.04M 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $3.20M 10-Q · filed 2022-08-15 | ||||
| 2022-01-04 | $3.20M 10-Q · filed 2022-05-16 | ||||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |